Clinical trial
A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)
NCT02365584 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)
- Lead sponsor
- Ipsen
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2015
- Completion date
- January 16, 2018
- Enrollment
- 43 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.